[go: up one dir, main page]

ES2044952T3 - Composiciones estabilizadas que contienen factor de crecimiento epidermico. - Google Patents

Composiciones estabilizadas que contienen factor de crecimiento epidermico.

Info

Publication number
ES2044952T3
ES2044952T3 ES87309748T ES87309748T ES2044952T3 ES 2044952 T3 ES2044952 T3 ES 2044952T3 ES 87309748 T ES87309748 T ES 87309748T ES 87309748 T ES87309748 T ES 87309748T ES 2044952 T3 ES2044952 T3 ES 2044952T3
Authority
ES
Spain
Prior art keywords
growth factor
compositions containing
stabilized compositions
solid
epidermic growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87309748T
Other languages
English (en)
Inventor
Amy L Finkenaur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethicon Inc
Original Assignee
Ethicon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/927,627 external-priority patent/US4717717A/en
Application filed by Ethicon Inc filed Critical Ethicon Inc
Application granted granted Critical
Publication of ES2044952T3 publication Critical patent/ES2044952T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A23C9/206—Colostrum; Human milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Dairy Products (AREA)

Abstract

COMPOSICIONES MEDICAS QUE CONTIENEN UN FACTOR DE CRECIMIENTO POLIPEPTICO, QUE TIENEN ACTIVIDAD MITOGENICA, SE ESTABILIZAN CONTRA PERDIDA DE ESTABILIDAD BIOLOGICA, EN PRESENCIA DE HUMEDAD, INCLUYENDO EN DICHAS COMPOSICIONES UNA CANTIDAD ESTABILIZANTE DE UN POLISACARIDO SOLUBLE EN AGUA, PREFERIBLEMENTE UN DERIVADO DE CELULOSA, TAL COMO METILCELULOSA O UNA HIDROXIALQUILCELULOSA, TAL COMO HIDROXIPROPILMETILCELULOSA.
ES87309748T 1986-11-05 1987-11-04 Composiciones estabilizadas que contienen factor de crecimiento epidermico. Expired - Lifetime ES2044952T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/927,627 US4717717A (en) 1986-11-05 1986-11-05 Stabilized compositions containing epidermal growth factor
US9645587A 1987-09-18 1987-09-18

Publications (1)

Publication Number Publication Date
ES2044952T3 true ES2044952T3 (es) 1994-01-16

Family

ID=26791728

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87309748T Expired - Lifetime ES2044952T3 (es) 1986-11-05 1987-11-04 Composiciones estabilizadas que contienen factor de crecimiento epidermico.

Country Status (13)

Country Link
EP (1) EP0267015B1 (es)
JP (2) JP2942227B2 (es)
KR (1) KR880005935A (es)
AU (1) AU614941B2 (es)
CA (1) CA1322328C (es)
DE (1) DE3781509T2 (es)
DK (1) DK579787A (es)
ES (1) ES2044952T3 (es)
GR (1) GR871700B (es)
MX (1) MX171861B (es)
NZ (2) NZ235556A (es)
PT (1) PT86075B (es)
SG (1) SG104292G (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019559A (en) * 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
US5472702A (en) * 1987-08-26 1995-12-05 United States Surgical Corporation Sterilization of growth factors
US5222978A (en) * 1987-08-26 1993-06-29 United States Surgical Corporation Packaged synthetic absorbable surgical elements
US5366081A (en) 1987-08-26 1994-11-22 United States Surgical Corporation Packaged synthetic absorbable surgical elements
US5306289A (en) * 1987-08-26 1994-04-26 United States Surgical Corporation Braided suture of improved characteristics
US5226912A (en) 1987-08-26 1993-07-13 United States Surgical Corporation Combined surgical needle-braided suture device
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
AU614137B2 (en) * 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
CA1330391C (en) * 1988-07-19 1994-06-28 Matthew E. Hermes Method for improving the storage stability of a polymeric article susceptible to hydrolic degradation and resulting article
US5034375A (en) * 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
GB8823649D0 (en) * 1988-10-07 1988-11-16 Geistlich Soehne Ag Chemical compounds
US5013714A (en) * 1988-12-15 1991-05-07 Lindstrom Richard L Viscoelastic solution
US5693625A (en) * 1989-03-09 1997-12-02 Therapeutiques Substitutives Method of regenerating cells and tissues using functionalized dextrans
FR2644066B1 (fr) * 1989-03-09 1994-05-13 Therapeutiques Substitutives Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
US5359831A (en) 1989-08-01 1994-11-01 United States Surgical Corporation Molded suture retainer
US5246104A (en) * 1989-08-01 1993-09-21 United States Surgical Corporation Molded suture retainer
US5422340A (en) * 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
IT1240683B (it) * 1990-04-26 1993-12-17 Zambon Spa Composizione farmaceutica contenente egf
CA2082420C (en) * 1990-05-30 2004-07-20 Harry N. Antoniades Wound healing composition comprising purified igf-i or igf-ii and a purified tgf-.beta.
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
GB9014871D0 (en) * 1990-07-05 1990-08-22 Erba Carlo Spa Drug delivery system for administering growth factor
NZ234439A (en) * 1990-07-10 1997-08-22 Pharmacia & Upjohn Ab Use of igf-1 to reduce fetal growth retardation in non human mammals
GB9015824D0 (en) * 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
US5714458A (en) * 1990-07-18 1998-02-03 Farmitalia Carlo Erba S.R.L. Stable pharmaceutical compositions containing a fibroblast growth factor
CA2055811A1 (en) * 1991-01-11 1992-07-12 Ross R. Muth Sterilization of growth factors
CA2059245C (en) * 1991-02-08 2004-07-06 Michael P. Chesterfield Method and apparatus for calendering and coating/filling sutures
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
WO1993008825A1 (en) * 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
GB9210574D0 (en) * 1992-05-18 1992-07-01 Ca Nat Research Council Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications
CA2104418A1 (en) * 1992-08-24 1994-02-25 Miguel A. Maestro Method of preparing hydrindane compounds and hydrindane-related compounds
CU22405A1 (es) * 1993-07-05 1996-01-31 Cigb Composicion cosmetica para el cuidado de la piel
US6277828B1 (en) * 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
DE4438015A1 (de) * 1994-10-25 1996-05-02 Boehringer Mannheim Gmbh Epithelzellenhaltiges Biomaterial und dessen Verwendung als Transplantat
US5904716A (en) * 1995-04-26 1999-05-18 Gendler; El Method for reconstituting cartilage tissue using demineralized bone and product thereof
US6572820B2 (en) 1996-02-05 2003-06-03 Asahi Medical Co., Ltd. Sterilization-protecting agent and sterilization method
WO1997032572A2 (en) * 1996-03-04 1997-09-12 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
NZ335005A (en) * 1997-08-01 2000-12-22 Toray Industries Method for stabilizing cytokine using a compound arabic acid or the like
IT1298758B1 (it) * 1998-03-19 2000-02-02 Angelini Ricerche Spa Soluzione umettante e lubrificante per uso oftalmico
EP1117378A2 (en) 1998-10-05 2001-07-25 The Penn State Research Foundation Compositions and methods for enhancing receptor-mediated cellular internalization
GB2344519B (en) * 1998-12-07 2004-05-19 Johnson & Johnson Medical Ltd Sterile therapeutic compositions
US20030228288A1 (en) 1999-10-15 2003-12-11 Scarborough Nelson L. Volume maintaining osteoinductive/osteoconductive compositions
KR100366439B1 (ko) * 2000-02-21 2003-01-09 주식회사 대웅 상피세포 성장인자를 유효성분으로 하는 안정한 약제학적조성물
US6309454B1 (en) 2000-05-12 2001-10-30 Johnson & Johnson Medical Limited Freeze-dried composite materials and processes for the production thereof
US9387094B2 (en) 2000-07-19 2016-07-12 Warsaw Orthopedic, Inc. Osteoimplant and method of making same
KR100426223B1 (ko) * 2000-10-27 2004-04-08 한건 수용성 펩타이드 약물의 건조 리포좀 조성물 및 그의 제조방법
US7323193B2 (en) 2001-12-14 2008-01-29 Osteotech, Inc. Method of making demineralized bone particles
IL157088A0 (en) 2001-01-30 2004-02-08 Orthogene Inc A composition containing synovial membrane tissue
CA2701551A1 (en) * 2001-08-10 2003-02-20 Masahiro Inohara Polysaccharide-containing compositions and use thereof
US7163691B2 (en) * 2001-10-12 2007-01-16 Osteotech, Inc. Bone graft
KR20050042032A (ko) * 2001-11-02 2005-05-04 세키스이가가쿠 고교가부시키가이샤 사이토카인 유도 재료 및 사이토카인 유도 용구
US20030109820A1 (en) * 2001-12-07 2003-06-12 Gross T. Daniel Hemostatic agent delivery system
KR20060031808A (ko) 2003-06-11 2006-04-13 오스테오테크, 인코포레이티드 뼈 임플란트 및 그의 제조 방법
AU2005235800B2 (en) * 2004-04-23 2011-08-04 Expedeon Limited Methods and kits for stabilising, protecting and solubilising proteins
EP1906986A4 (en) 2005-06-17 2011-02-23 Regenerx Biopharmaceuticals LKKTET AND / OR LKKTNT PEPTIDE COMPOSITIONS LYOPHILIZED OR PROVIDED IN A LYOPHILIC FORM
JP5357424B2 (ja) * 2005-07-20 2013-12-04 協和メデックス株式会社 生体試料中のペプチドの安定化方法
WO2007056671A1 (en) 2005-11-02 2007-05-18 Osteotech, Inc. Hemostatic bone graft
KR100748390B1 (ko) * 2005-11-14 2007-08-10 주식회사 대웅 상피세포성장인자를 포함하는 상처치료용 서방성 필름 제형
KR100784134B1 (ko) * 2006-10-09 2007-12-12 주식회사 대웅 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
JP2008200195A (ja) * 2007-02-19 2008-09-04 Daitaro Fukuoka 形成施術用糸およびこれを用いた形成施術方法
US20090192554A1 (en) 2008-01-29 2009-07-30 Confluent Surgical, Inc. Bioabsorbable block copolymer
WO2010048610A2 (en) 2008-10-24 2010-04-29 Osteotech, Inc. Compositions and methods for promoting bone formation
CN102389392B (zh) * 2011-11-02 2012-10-24 珠海亿胜生物制药有限公司 重组牛碱性成纤维细胞生长因子眼用凝胶
DK2819682T3 (en) * 2012-03-01 2017-08-21 Firststring Res Inc TOPICAL GELLS CONTAINING ALPHA-CONNEXIN C-TERMINAL (ACT) PEPTIDES
CN104740677B (zh) * 2015-04-23 2017-06-06 广西达庆生物科技股份有限公司 一种皮肤医用修复敷料及其制备方法
CN106720379A (zh) * 2016-12-05 2017-05-31 中国科学院兰州化学物理研究所 一种驼血多肽奶片及其制备方法
US11241480B2 (en) * 2017-01-26 2022-02-08 Washington University Methods for modulation of dietary and microbial exposure with compositions comprising an EGFR ligand
EP3902573A4 (en) * 2018-12-28 2022-08-24 Excel Med, LLC Biological scaffold and method for fabricating the same
CN110075054A (zh) * 2019-06-06 2019-08-02 山东天源人乳库科技发展有限公司 一种来源于人乳的人源性生长因子修复制剂及其制备方法
CN116710474A (zh) 2020-10-22 2023-09-05 撒凯尔生物公司 肽制剂及其眼科用途
US20230031385A1 (en) * 2021-07-20 2023-02-02 National Health Research Institutes Storage media for preservation of corneal tissue

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179497A (en) * 1973-12-17 1979-12-18 Merck & Co., Inc. Solid state ophthalmic medication
EP0140998B1 (en) * 1983-11-02 1989-11-15 Nihon Chemical Research Kabushiki Kaisha Ophthalmic preparations
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
EP0193917A3 (en) * 1985-03-06 1987-09-23 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration

Also Published As

Publication number Publication date
SG104292G (en) 1992-12-24
MX171861B (es) 1993-11-22
EP0267015A2 (en) 1988-05-11
NZ235556A (en) 1991-06-25
JPS63152324A (ja) 1988-06-24
DK579787D0 (da) 1987-11-04
NZ222413A (en) 1991-06-25
JPH10167980A (ja) 1998-06-23
PT86075B (pt) 1990-11-07
DE3781509D1 (de) 1992-10-08
GR871700B (en) 1988-03-04
CA1322328C (en) 1993-09-21
PT86075A (en) 1987-12-01
KR880005935A (ko) 1988-07-21
AU614941B2 (en) 1991-09-19
JP2942227B2 (ja) 1999-08-30
JPH11255663A (ja) 1999-09-21
AU8064187A (en) 1988-05-12
EP0267015B1 (en) 1992-09-02
JP2988925B2 (ja) 1999-12-13
DE3781509T2 (de) 1993-01-07
DK579787A (da) 1988-05-06
EP0267015A3 (en) 1990-01-17

Similar Documents

Publication Publication Date Title
ES2044952T3 (es) Composiciones estabilizadas que contienen factor de crecimiento epidermico.
HUT43240A (en) Fungicidal, insecticidal, nematocidal and plant growth regulating compositions comprising acryl acid derivatives as active substance and process for preparing the active substances
LU90192I2 (fr) Desirudine et ses sels et dérivés pharmaceutiquement acceptables (revasc)
FI864665L (fi) Lääkeaineille tarkoitettuja kantajakoostumuksia, jotka sisältävät hydroksipropyyliselluloosaeettereitä
SE8804629D0 (sv) New therapeutically active compounds
SE8300623D0 (sv) Farmaceutisk komposition innehallande stabil mikrokristallin cis-platina(ii)-diammindiklorid (cisplatin)
IT1200589B (it) Derivati naturali attivita farmagologica
ES2054679T3 (es) Vacunas.
ES2167751T3 (es) Preparaciones de insulina conteniendo un halogenuro.
DE3783356D1 (de) Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
NO865079L (no) Fremgangsmaate for fremstilling av stabiliserte humanvevplasminogenaktivatorpreparater.
IT1185550B (it) Miscele non polverose di sfarinati o farine con principi attivi per mangimistica
NO870772D0 (no) Vevplasminogenaktivator for normale humane tykktarmceller.
DK0490549T3 (da) Stabilisering af calcitonin-holdige farmaceutiske præparater
HUT44410A (en) Insecticidal, acaricidal, nematocidal, fungicidal compositions comprising pyridazinone derivatives as active substance and process for preparing the active substances
IT1216797B (it) Composizioni stabili allo stoccaggio di assorbenti uv
ATE113849T1 (de) Verwendung von polysacchariden in zubereitungen zur wundbehandlung.
DK116386D0 (da) Polyprenylforbindelser, fremgangsmaader til deres fremstilling og farmaceutiske kompositioner indeholdende forbindelserne
IL81574A0 (en) Derivatives of 2-cyano benzimidazole,process for their preparation,fungicidal compositions containing the same and compositions containing additional fungicides
FI853962L (fi) Buffrade glutaraldehyd innehaollande steriliserande och desinficerande kompositioner.
BR0009636A (pt) Preparação de procarboxipeptidase b pancreática, formas iso e muteìnas das mesmas e seu emprego
ES2053573T3 (es) Composiciones rodenticidas que contienen derivados de 1,4-naftoquinona.
ATE49980T1 (de) Verwendung von gonadoliberin und gonadoliberinagonisten zur herstellung einer pharmazeutischen zubereitung.
MA20974A1 (fr) Derives propargyloxybenzenes, leur preparation et compositions fongicides les contenant
DE3778824D1 (de) Herstellung von celluloseaethern.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 267015

Country of ref document: ES